Sponsored Content

News this week that US-based Fate Therapeutics’ (NASDAQ:FATE) has dosed the first ever patient in the United States with an off-the-shelf cell therapy derived from induced pluripotent stem cell (iPSC) is encouraging – particularly for stem cell biotech Cynata Therapeutics (ASX:CYP).

Fate’s product is a natural killer (NK) cell product for the treatment of cancer. Fate is also developing further iPSC-derived products, including a chimeric antigen receptor (CAR) NK cell product, for off-the-shelf cancer immunotherapy.

Fate’s products showcase the ability to mass produce uniformly engineered cell therapies using an iPSC starting material.

Like Cynata, Fate’s product is infinitely expandable as it uses iPSCs as its starting material that enable the unlimited and consistent expansion of the cells.

Fate’s proprietary iPSC product platform enables mass production of off-the-shelf, engineered, homogeneous immunotherapy cell products, particularly for cancer.

In Cynata’s case its Cymerus platform uses iPSCs to mass-manufacture mesenchymal stem cells (MSCs) which are one of the more clinically promising type of cell therapies.

Cynata has demonstrated the safety and efficacy profile of its MSCs in the treatment of the often-fatal graft-versus-host disease (GvHD) and is now heading towards phase two clinical trials in GvHD, osteoarthritis and critical limb ischemia (CLI).

Cynata’s MSCs have also shown promising results in preclinical studies of ameliorating the effects of cytokine release syndrome (CRS) – a potentially severe and life-threatening adverse reaction to cancer immunotherapy that includes CAR-T therapy.

Read more: Cynata study places it in hot cancer immunotherapy sector

In the case of Fate, the first patient administered showed the treatment was ‘well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period’. The trial is expected to dose up to 64 patients for the treatment of advanced solid tumors.

This outcome provides further support for Cynata’s iPSC approach and the willingness of the US regulators to progress to the trial is also an indication of the growing support and acceptance of stem cell treatments of this kind.

Australia has also demonstrated its support of stem cell therapies with the government’s latest Australian Stem Cell Therapies Mission that has pledged $150 million to support radical stem cell research.

Read more: New government initiative to give cash injection to stem cell industry

This content is produced by Star Investing in commercial partnership with Cynata Therapeutics. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.